Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?

被引：1

作者：

Abdallah, Mostafa ^{[1
]}

Reichard, Kaaren ^{[1
]}

Gangat, Naseema ^{[1
]}

Tefferi, Ayalew ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

关键词：

TP53; MUTATIONS; PREVALENCE;

D O I：

10.1038/s41408-024-01027-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 50 条

[21] Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring
Jaedersten, Martin
Karsan, Aly
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (02): : 177 - 180
[22] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
Martinez-Hoyer, Sergio
Deng, Yu
Parker, Jeremy
Jiang, Jihong
Docking, Roderick
Mo, Angela
Gharaee, Nadia
Jadersten, Martin
Kulasekararaj, Austin
Malcovati, Luca
List, Alan
Hellstrom-Lindberg, Eva
Platzbecker, Uwe
Karsan, Aly
EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
[23] Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide
Merkerova, Michaela Dostalova
Krejcik, Zdenek
Belickova, Monika
Hrustincova, Andrea
Klema, Jiri
Stara, Eliska
Zemanova, Zuzana
Michalova, Kyra
Cermak, Jaroslav
Jonasova, Anna
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (01) : 35 - 43
[24] Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment
Krejcik, Zdenek
Belickova, Monika
Hrustincova, Andrea
Klema, Jiri
Zemanova, Zuzana
Michalova, Kyra
Cermak, Jaroslav
Jonasova, Anna
Merkerova, Michaela Dostalova
CANCER GENETICS, 2015, 208 (04) : 156 - 161
[25] Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q)
Adema, Vera
Palomo, Laura
Fuster-Tormo, Francisco
Benito, Rocio
Salgado, Rocio
Such, Esperanza
Kosmider, Olivier
Larrayoz, Maria Jose
Xicoy, Blanca
Janusz, Kamila
Maietta, Paolo
Neef, Alexander
Amunchastegui, Beatriz Arrizabalaga
Fontenay, Michaela
Gomez-Marzo, Paula
Del Rey, Monica
Ibanez, Mariam
Haro, Nuri
Mallo, Mar
Zamora, Lurdes
Visconte, Valeria
Maciejewski, Jaroslaw P.
Fenaux, Pierre
Cervera, Jose
Calasanz, Maria Jose
Hernandez-Rivas, Jesus Maria
Cigudosa, Juan
Sole, Francesc
BLOOD, 2016, 128 (22)
[26] Familial occurrence of myelodysplastic syndrome with del(5q)
Volpicelli, Paola
Latagliata, Roberto
Carmosino, Ida
Breccia, Massimo
Vozella, Federico
Mancini, Marco
Cannella, Laura
Alimena, Giuliana
LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1143 - 1145
[27] Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
Komrokji, Rami S.
Al Ali, Najla H.
Padron, Eric
Lancet, Jeffrey E.
List, Alan F.
BLOOD, 2011, 118 (21) : 1195 - 1195
[28] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
Scharenberg, C.
Karimi, M.
Jansson, M.
Walldin, G.
Woll, P.
Jacobsen, S. E.
Hellstrom-Lindberg, E.
LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
[29] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
Kelaidi, Charikleia
Park, Sophie
Brechignac, Sabine
Mannone, Lionel
Vey, Norbert
Dombret, Herve
Aljassem, Lina
Starnatoullas, Aspasia
Ades, Lionel
Giraudier, Setphane
de Botton, Stephane
Mahe, Beatrice
Lepelley, Pascale
Picard, Fracoise
Leroux, Genevieve
Daniel, Marie-Threrese
Bouscary, Didier
Dreyfus, Francois
Fenaux, Pierre
BLOOD, 2006, 108 (11) : 757A - 757A
[30] Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome with Isolated Del(5q) with Lenalidomide, Bortezomib, and Dexamethasone
Washington, Nyomi
Shippey, Eugen A., III
Osswald, Michael B.
BLOOD, 2020, 136

← 1 2 3 4 5 →